Oragenics (OGEN) Stock Price, News & Analysis

Company Overview

Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.

Key Stats

• Today's Range: $0.16 to $0.32
• 50-Day Range: $0.12 to $0.25
• 52-Week Range: $0.11 to $2.52
• Volume: 271.22 million shs
• Average Volume: 2.78 million shs
• Market Capitalization: $3.59 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Oragenics Stock Analysis - MarketRank™

Oragenics scored higher than 3% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Oragenics.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Oragenics is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Oragenics is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Oragenics has a P/B Ratio of 0.27. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.41% of the float of Oragenics has been sold short.

Short Interest Ratio / Days to Cover

Oragenics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Oragenics has recently increased by 33.69%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Oragenics does not currently pay a dividend.

Dividend Growth

Oragenics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.41% of the float of Oragenics has been sold short.

Short Interest Ratio / Days to Cover

Oragenics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Oragenics has recently increased by 33.69%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Oragenics this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for OGEN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Oragenics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Oragenics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.90% of the stock of Oragenics is held by insiders.

Percentage Held by Institutions

Only 18.71% of the stock of Oragenics is held by institutions.

OGEN Stock Analysis - Frequently Asked Questions

How have OGEN shares performed this year?

Oragenics' stock was trading at $0.3693 on January 1st, 2025. Since then, OGEN shares have decreased by 54.8% and is now trading at $0.1670.
View the best growth stocks for 2025 here.

How were Oragenics' earnings last quarter?

Oragenics, Inc. (NYSE:OGEN) released its earnings results on Monday, August, 16th. The company reported ($1.80) earnings per share for the quarter, beating analysts' consensus estimates of ($2.40) by $0.60.

When did Oragenics' stock split?

Oragenics's stock reverse split on Monday, January 23rd 2023. The 1-60 reverse split was announced on Monday, January 23rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

How do I buy shares of Oragenics?

Shares of OGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Oragenics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Oragenics investors own include Tonix Pharmaceuticals (TNXP), Onconova Therapeutics (ONTX), iBio (IBIO), Jaguar Health (JAGX), NIO (NIO), Bionano Genomics (BNGO) and Vaxart (VXRT).

Company Calendar

• Last Earnings: 8/16/2021
• Today: 6/02/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:OGEN
• Previous Symbol: NYSE:OGEN
• CIK: 1174940
• Web: www.oragenics.com
• Phone: 813-286-7900
• Fax: 813-286-7904
• Employees: 5
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.12)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$20.66 million
• Net Margins: N/A
• Pretax Margin: -243,950.00%
• Return on Equity: -2,087.95%
• Return on Assets: -486.56%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.93
• Quick Ratio: 1.93

Sales & Book Value

• Annual Sales: $40,000.00
• Price / Sales: 89.66
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.61 per share
• Price / Book: 0.27

Miscellaneous

• Outstanding Shares: 21,475,000
• Free Float: 10,979,000
• Market Cap: $3.59 million
• Optionable: N/A
• Beta: 1.16